Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Dietary modification is central to managing 

, but the optimal approach remains unclear. Continuous calorie restriction has long been the standard, with well-established benefits for glycemic control and weight loss. However, more recently, intermittent fasting strategies have gained popularity as potentially simpler alternatives that may offer similar metabolic benefits without daily calorie tracking.

Currently, there is a lack of direct comparisons between intermittent fasting and calorie restriction in patients with type 2 diabetes, and uncertainty remains around their relative effects on HbA1c, weight, and cardiometabolic risk, as well as safety considerations like hypoglycemia. To address this gap, Lyluma Ishfaq, MD, an internal medicine resident at Central Michigan University, and colleagues conducted a systematic review and meta-analysis, with findings presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026.

Seeking to compare the effects of intermittent fasting versus calorie restriction on glycemic control, weight, and cardiometabolic risk factors in adults with type 2 diabetes, investigators searched PubMed and ClinicalTrials.gov for randomized trials directly comparing both strategies for ≥12 weeks. They excluded nonrandomized studies, trials without a calorie restriction comparator, and trials in prediabetes or without type 2 diabetes-only data. Given that only 2 heterogeneous RCTs met the inclusion criteria, investigators opted to perform a descriptive quantitative synthesis rather than a single pooled estimate.

The first included study was a randomized noninferiority trial conducted at the University of South Australia in which adults with type 2 diabetes were randomized in a 1:1 ratio to parallel diet groups of intermittent energy restriction or continuous energy restriction. The second study was a 6-month randomized clinical trial conducted at the University of Illinois Chicago that enrolled adults with obesity and type 2 diabetes and randomized them to 1 of 3 groups: 8-hour time-restricted eating from 12pm to 8pm only, calorie restriction of 25% daily, or control.

Among 212 participants across both trials (n = 105 intermittent fasting; n = 107 calorie restriction), investigators noted HbA1c decreased similarly with both strategies. In the first study, 12-month HbA1c declined by −0.5% with calorie restriction and −0.3% with intermittent fasting, a between-group difference of 0.2% (90% CI, −0.2 to 0.5), meeting the prespecified equivalence criterion. In the second study, 6-month HbA1c changed by −0.72% with intermittent fasting, −0.75% with calorie restriction, and 0.19% with control, with no significant difference between intermittent fasting and calorie restriction (mean difference, 0.04%; 95% CI, −0.64 to 0.72).

Of note, weight loss slightly favored intermittent fasting (−6.8 vs −5.0 kg at 12 months in the first study; −4.3% vs −2.5% at 6 months in the second study), though these differences were not statistically significant. Fasting glucose, lipids, blood pressure, and hypoglycemia rates were additionally similar between groups.

“In adults with T2D, current randomized evidence suggests that IF achieves HbA1c reductions equivalent to daily calorie restriction, with a trend toward slightly greater weight loss but no consistent additional metabolic advantage. Both strategies appear safe when hypoglycemia-inducing medications are proactively adjusted,” ? and colleagues wrote. “Larger, longer RCTs are needed to define differential effects on long-term glycemic durability, cardiovascular outcomes, and patient-centered adherence.”

Ishfaq L, Khan A, Zargar MN, et al. Metabolic Outcomes of Intermittent Fasting Versus Continuous Calorie Restriction in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas, Nevada, April 22-24, 2026.

Carter S, Clifton PM, Keogh JB. Effect of Intermittent Compared With Continuous Energy Restricted Diet on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Noninferiority Trial. 

 2018;1(3):e180756. doi:10.1001/jamanetworkopen.2018.0756

Pavlou V, Cienfuegos S, Lin S, et al. Effect of Time-Restricted Eating on Weight Loss in Adults With Type 2 Diabetes: A Randomized Clinical Trial. 

 2023;6(10):e2339337. doi:10.1001/jamanetworkopen.2023.39337

Articles

Intermittent fasting and continuous calorie restriction show comparable glycemic benefits in adults with type 2 diabetes based on limited randomized evidence. Across two heterogeneous RCTs totaling 212 participants, HbA1c reductions were similar at 6 and 12 months, meeting noninferiority/equivalence parameters where prespecified. Weight loss numerically favored intermittent fasting but without statistical separation. Cardiometabolic markers—including fasting glucose, lipids, and blood pressure—were broadly similar, as were hypoglycemia rates when glucose-lowering regimens were proactively adjusted. Larger, longer trials are needed to assess durability, outcomes, and adherence.

RCTs show intermittent fasting and calorie restriction yield similar HbA1c and cardiometabolic outcomes in type 2 diabetes, with modest, nonsignificant weight differences.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Intermittent Fasting, Calorie Restriction Deliver Similar Cardiometabolic Outcomes in T2D

Craig Anderson, PhD, is a professor of neurology and epidemiology and the director of the Brain Health Program at the George Institute.

Triple-Combination Blood Pressure Pill Reduces Ischemic Stroke Risk, With Craig Anderson, PhD

GMRx2, a combination of 3 low-dose blood pressure medications in a single pill, has proven its efficacy in substantially reducing 

 risk in patients with intracerebral hemorrhage (ICH), according to data from the TRIDENT phase 3 trial.

Intracerebral hemorrhage is the direct contributor to a disproportionate percentage of stroke-related morbidity and mortality. Among its primary causes is chronic 

, another famously under-managed condition affecting a substantial proportion of the population. Blood pressure reduction is therefore a cornerstone of modern ICH treatment and prevention of further stroke.

“One of the problems we’ve had in blood pressure control for secondary prevention after stroke is just achieving the targets, whether that’s <140 or, more stringently, <130,” Craig Anderson, PhD, professor of neurology and epidemiology, director of the Brain Health Program at the George Institute, and principal investigator, told 

 in an exclusive interview. “It’s very challenging to do that in clinical practice – most patients will require multiple drugs and that causes problems with medication adherence. Our trial shows that achieving blood pressure <130 is achievable, and that the triple pill approach can do it very effectively compared to standard treatment.”

The Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) was a multicenter, international, double-blinded, placebo-controlled, parallel-group, randomized controlled trial comparing more intensive blood pressure control through the “triple pill” GMRx2 on top of standard care to treatment with matched placebo. Anderson and colleagues aimed to assess the triple pill’s efficacy and safety in preventing recurrent ischemic strokes in patients with a history of ICH and high, normal, or low-grade hypertension. The trial was conducted across 58 locations worldwide.

Patients were eligible for inclusion if they had a history of primary ICH confirmed via imaging and an average of 2 resting systolic blood pressure (SBP) levels measured 5 minutes apart in the range 130-160 mmHg, among other criteria. Patients taking an ACE inhibitor which could not be switched to a study alternative or who had severe hepatic impairment, significant hyperkalemia, or hyponatremia, among other criteria, were excluded.

Enrolled patients were randomly assigned to receive either GMRx2 – a combination of telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg – or placebo, both of which were daily pills taken orally for an average of 72 months. The study’s primary outcome was time to first occurrence of recurrent stroke, whether ischemic or hemorrhagic. Secondary outcomes included time to first occurrence of recurrent ICH, mortality, major adverse cardiovascular events, and change in SBP, among others.

A total of 1670 patients were ultimately enrolled, all of whom had SBP within 130-160 mmHg. Over the course of the study, stroke occurred in 4.6% of patients receiving GMRx2 versus 7.4% receiving placebo. Major adverse cardiovascular events occurred in 6.6% of GMRx2 recipients compared to 9.8% of placebo recipients, resulting in a 33% reduction. Additionally, Anderson and colleagues noted a 9 mmHg greater SBP reduction in the GMRx2 arm.

“The important thing about TRIDENT was the additional benefit that was achieved by most of the patients already on a treatment,” Anderson told 

. “Most people were on multiple drugs, and most people were within clinicians’ understanding of good control. And even with that, the addition of GMRx2 allowed them to achieve this amazingly extra benefit.”

Editors’ Note: Anderson reports disclosures with the National Health and Medical Research Council of Australia, the Medical Research Council of the UK, Takeda, Credit, Genesis, and Penumbra, Inc.

Anderson C, Chow C, de Silva H, et al. Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage. 

. 2026;394(16):1571-1582. doi:10.1056/NEJMoa2515043

Schrag M, Kirshner H. Management of Intracerebral Hemorrhage: JACC Focus Seminar. 

The George Institute. Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT). ClinicalTrials.gov Identifier: NCT02699645. Updated September 12, 2025. Accessed April 22, 2026. 

https://clinicaltrials.gov/study/NCT02699645

Videos

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Growth hormone deficiency in adults remains a commonly underappreciated and underrecognized diagnosis in endocrinology. Despite quietly eroding body composition, metabolic health, and quality of life, it has long been managed with a daily injection regimen that many patients do not sustain.

With lonapegsomatropin (Skytrofa), developed as TransCon hGH, earning US Food and Drug Administration approval for adult GH deficiency in July 2025, clinicians now have a once-weekly alternative. New long-term extension data presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 by Julie Silvertein, MD, a Professor of Medicine and Neurological Surgery and Medical Director of the Pituitary Center at Washington University, offer a more comprehensive picture of how it performs over time.

 Once-weekly prodrug of somatropin (human growth hormone)

 Uses a pH- and temperature-sensitive linker to transiently inactivate somatropin; active, unmodified hGH is released gradually over 7 days

 August 2021, for pediatric GH deficiency; July 28, 2025, for replacement of endogenous GH in adults with GH deficiency

 Phase 3 foresiGHt trial, in which lonapegsomatropin demonstrated superiority over placebo on trunk fat reduction and lean mass gain at 38 weeks

 Ascendis Pharma (marketed as Skytrofa in the US)

Lonapegsomatropin’s approval for this indication built upon previous August 2021 approval for the treatment of pediatric growth hormone deficiency in children ≥ 1 year of age weighing ≥ 26 pounds. The latest approval was based on results from foresiGHt, a phase 3 randomized, parallel-arm, placebo-controlled, double-blind, and active-controlled clinical trial that compared the efficacy and safety of weekly lonapegsomatropin with weekly placebo and daily somatropin in adults with growth hormone deficiency.

The trial randomly assigned 259 adults with growth hormone deficiency aged 23 to 80 years old in a 1:1:1 ratio, titrated to receive a target fixed dose of lonapegsomatropin, placebo, or daily hGH. Randomization was based on age and oral estrogen intake, with approximately equivalent hGH mg/week for lonapegsomatropin and daily hGH.

Of the 248 participants who completed treatment in the foresiGHt trial, 220 (88.7%) continued into the extension trial for up to 90 weeks and 202 (91.8%) participants completed 52 weeks of treatment in the extension trial.

Across 236 lonapegsomatropin-treated participants from both trials, the most common AEs were nasopharyngitis (9.7%), upper respiratory tract infection (9.3%), headache (8.1%), COVID-19 (7.2%), arthralgia (6.4%), and injection site reactions (5.1%). Most were mild or moderate, and treatment discontinuations due to AEs occurred in 3.8% of participants.

Results showed mean hemoglobin A1c remained stable within the reference range throughout all 90 weeks. Additionally, immunogenicity was low, with anti-hGH and anti-lonapegsomatropin antibodies each detected in 3.4% of participants and anti-PEG binding antibodies in 0.9%. All were low titer, transiently detected, and no neutralizing antibodies were identified.

Of note, weekly average IGF-1 SDS was maintained within the normal reference range through week 90 across all groups. Participants previously on placebo showed appropriate IGF-1 increases after initiating lonapegsomatropin, converging toward the reference range during re-titration and remaining stable thereafter.

Additionally, body composition improved across all 3 prior-treatment groups from the foresiGHt baseline through week 90, with reductions in trunk percent fat, trunk fat mass, and visceral adipose tissue, alongside gains in total body lean mass and trunk lean mass.

Patient-reported outcomes also reflected durable benefit. Using TRIM-AGHD, responder rates at week 90, defined as a reduction of ≥ 10 points from baseline, were 43.5%, 40.6%, and 35.8% in the lonapegsomatropin/lonapegsomatropin, placebo/lonapegsomatropin, and somatropin/lonapegsomatropin groups, respectively, with mean score reductions of approximately 19-23 points across groups.

Silverstein JM, Gilis-Januszewska A, Doknic M, et al. Long-term Safety and Efficacy of Lonapegsomatropin in Adults With Growth Hormone Deficiency: Results From a 52-Week Open-Label Extension Trial. Presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas, Nevada, April 22-24, 2026.

Brooks A. FDA Approves Lonapegsomatropin-tcgd (Skytrofa), Formerly TransCon hGH, for Adult Growth Hormone Deficiency. HCPLive. July 28, 2025. Accessed April 22, 2026. 

https://www.hcplive.com/view/fda-approves-lonapegsomatropin-tcgd-skytrofa-formerly-transcon-hgh-for-adult-growth-hormone-deficiency

Adult growth hormone deficiency is frequently overlooked and historically burdensome to treat because of daily injections. Once-weekly lonapegsomatropin, FDA-approved in July 2025, now has longer-term extension data through 90 weeks following the phase 3 foresiGHt program. Safety was consistent with mostly mild-to-moderate infections, headache, arthralgia, and limited injection-site reactions, with few discontinuations. Glycemic control and IGF-1 SDS remained stable within reference ranges, immunogenicity was low, and durable improvements were observed in body composition and patient-reported treatment impact.

Results from the 52-week open-label extension trial highlight strong safety and efficacy outcomes with lonapegsomatropin in adults with growth hormone deficiency.

Lonapegsomatropin Proves Long-Term Benefit for Adult GHD in Phase 3 foresiGHt Extension Trial

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for children aged 2 to 11 years with 

 (CSU) that remains symptomatic despite H1 antihistamine treatment, according to a joint announcement from Regeneron and Sanofi.

The decision, which was announced on April 22, 2026, extends the drug’s prior US CSU indication in adults and adolescents aged 12 years and older.

“With this approval, Dupixent has become the first biologic medicine in the U.S. for young children suffering from uncontrolled chronic spontaneous urticaria, an unpredictable skin disease that impacts quality of life during these children’s most formative years,” George D. Yancopoulos, MD, PhD board co-chair, president, and chief scientific officer at Regeneron, and a principal inventor of Dupixent, said in a statement.

According to the announcement, the pediatric label expansion was based primarily on the phase 3 LIBERTY-CUPID program, using efficacy and safety extrapolation from randomized trials in older patients and pharmacokinetic data from the single-arm CUPIDKids study in children aged 2 to 11 years.

In Study A and Study C, both replicate double-blind, placebo-controlled trials in patients aged 6 years and older who were symptomatic despite antihistamines and naïve to anti-IgE therapy, dupilumab significantly improved weekly itch severity score (ISS7) and weekly urticaria activity score (UAS7) vs placebo at week 24, the companies said. In adults and adolescents, dupilumab also increased the likelihood of well-controlled disease (UAS7 ≤6) and complete response (UAS7 = 0) at 24 weeks.

Study B enrolled patients aged 12 years and older who were symptomatic despite antihistamines and were inadequate responders or intolerant to anti-IgE therapy, providing additional safety data, according to the release. CUPIDKids was a single-arm phase 3 trial designed to assess safety, efficacy, and pharmacokinetics over 24 weeks; its primary endpoint was serum dupilumab concentration over time, including trough levels at weeks 12 and 24. No numerical efficacy results from CUPIDKids were disclosed in the release.

Additional Considerations for Dupilumab in CSU

International guidance generally recommends second-generation H1 antihistamines as first-line therapy, with dose escalation and then biologic treatment for refractory disease. Omalizumab has been a standard biologic option for antihistamine-refractory CSU in older patients, although pediatric options for children younger than 12 years have been more constrained.

Dupilumab is a fully human monoclonal antibody that blocks interleukin 4 and interleukin 13 signaling. It is already approved across multiple type 2 inflammatory diseases, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.

 Its role in CSU has been of interest because not all patients respond adequately to antihistamines or anti-IgE therapy, and CSU pathobiology may include overlapping inflammatory pathways beyond mast cell and IgE-mediated signaling.

Pediatric PK trial: CUPIDKids, single-arm  

Prior CSU approval: adults, age 12 years and up  

The sponsors described safety findings in the CSU development program as generally consistent with the established dermatologic safety profile of dupilumab.

 In Studies A, B, and C, the most common adverse event (AE) occurring more often with dupilumab than placebo was injection-site reaction.

The companies also said no new AEs were identified in children aged 2 to 11 years with CSU, with pediatric safety additionally supported by experience in other approved indications.

“Dupixent is now approved for 9 different allergy-related conditions, from asthma to atopic dermatitis, and this is the fifth of these indications now extended to young children,” The FDA’s authorization reinforces our medicine’s well-established safety profile and potential to transform outcomes for chronic diseases driven in part by type 2 inflammation impacting some of the most vulnerable populations. As the most widely used innovative branded antibody medicine, Dupixent has the potential to change yet another treatment paradigm.”

Regeneron Pharmaceuticals, Inc; Sanofi. Dupixent (dupilumab) approved in the U.S. as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria (CSU). GlobeNewswire. April 22, 2026. Accessed April 22, 2026. 

https://www.globenewswire.com/news-release/2026/04/22/3279470/0/en/dupixent-dupilumab-approved-in-the-u-s-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria-csu.html

Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma: LIBERTY ASTHMA TRAVERSE. Eur Respir J. 2022;60(3):2102791.

The FDA has expanded dupilumab’s chronic spontaneous urticaria indication to children aged 2–11 years who remain symptomatic despite H1 antihistamines, extending prior approval in adolescents and adults. The decision addresses a major therapeutic gap for antihistamine-refractory pediatric CSU, where biologic options have been limited. Support came primarily from the phase 3 LIBERTY-CUPID program, leveraging efficacy/safety extrapolation from patients aged ≥6 years and pharmacokinetic bridging from the single-arm CUPIDKids study. Safety appeared consistent with dupilumab’s established profile.

FDA approved dupilumab for children aged 2 to 11 years with chronic spontaneous urticaria uncontrolled by H1 antihistamines.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

FDA News

FDA Expands Dupilumab to Children Aged 2 to 11 Years With Uncontrolled CSU

Anick Bérard PhD, a researcher at CHU Sainte-Justine in Montreal, professor at the University of Montreal, and an adjunct professor Université Claude Bernard Lyon 1.

ICS Not Linked to Birth Defect Risk in Early Pregnancy, With Anick Bérard, PhD

First-trimester exposure to inhaled corticosteroid (ICS) monotherapy, montelukast, and combination therapies with long-acting beta agonists (LABA) did not show an increased risk of major congenital malformations compared with no

 medication use, according to new population-based data.

, Anick Bérard, PhD, from CHU Sainte-Justine, described these results as “reassuring.” She mentioned how many women with unexpected pregnancies may not find out that they are pregnant until 6 or 7 weeks later. However, this data shows that taking asthma medication during pregnancy is safe.

“The GINA guidelines say asthmatic women should be treated in pregnancy, and our study [with] a large cohort [is]… confirming what the guidelines are saying,” Bérard said. She noted that smaller datasets originally informed these guidelines, standing for Global Initiative for Asthma, whereas the current study provides confirmation using a substantially larger cohort.

Bérard and colleagues’ analysis included a large cohort of > 44,000 singleton births among women with asthma and compared multiple commonly used controller therapies during the first trimester. Regimens included montelukast, inhaled corticosteroids (ICS), ICS plus long-acting beta agonists (LABA), and montelukast plus ICS plus LABA combination.

She also cautioned that the study does not address all pregnancy outcomes, such as preterm birth or low birth weight, which require further investigation. Additionally, she noted that the cohort largely included women with private insurance, indicating a higher socioeconomic profile that may limit generalizability.

Overall, the data support ongoing use of ICS monotherapy and ICS/LABA combinations when clinically indicated.

“It's reassuring for prescribers, but also for pregnant women themselves, because we're all worried about major congenital malformation,” Bérard said. “The quality of life and health of the mother is as important as the health of the fetus, although in pregnancy, we prescribe for a maternal condition, but we don't always worry about the health of the mom. We worry about the health of the unborn child. Results like ours will put women at ease that they can, and they should be treated. It will have a beneficial impact on themselves, but it will not have an impact on their fetus, at least during the first trimester.”

Watch part 1 of our interview with Bérard here: 

Asthma Controllers Safe in First Trimester, With Anick Bérard, PhD

Jiao XF, Leal LF, Ducharme FM, Tse SM, Bérard A. First-trimester asthma controller medication use and major congenital malformation risk in offspring of women with asthma: A nationwide population-based cohort study. 

In an interview, Bérard discusses cohort data showing no increased risk of major congenital malformations with ICS or ICS/LABA use in first trimester.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Rachael Sood, NP, is a diabetes nurse practitioner and Owner and CEO of The Diabetes Collective.

Sood discusses the FDA expansion of teplizumab to children as young as age 1 with stage 2 T1D and the implications for early intervention and delaying disease progression.

Type 1 Diabetes

Teplizumab Expansion Redefines Early Type 1 Diabetes Intervention, With Rachael Sood, NP

Rory Sayres, PhD, is a researcher in the Health AI group in Google Research who focuses on intelligence augmentation of medical experts using machine-learning-based assistance.

This interview highlights new data assessing whether artificial intelligence (AI)–powered tools can help consumers better understand dermatology cases.

AI Tool Use Linked with Understanding of Skincare Issues, With Rory Sayres, PhD, and Yun Liu, PhD

Propensity-matched data link empagliflozin to lower risk of CV events, AKI, and other outcomes versus dapagliflozin in type 2 diabetes.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Real-World Analysis Links Empagliflozin to Lower Cardiorenal Event Risk Versus Dapagliflozin in T2D

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

A recent presentation at AACE 2026 highlights the drastically increased risk of mortality, sepsis, diabetic ketoacidosis, and recurrent acute pancreatitis after GLP-1 initiation.

GLP-1 Use in Patients with Prior Alcohol-Related Pancreatitis Dangerously Increases DKA, Mortality Risk

A recent study from AACE 2026 has indicated the value of bariatric surgery in adults with type 1 diabetes – and emphasized the need for closer perioperative management.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Bariatric Surgery in T1D Causes Sustained Weight Loss, Improves Comorbidities

Alva discusses infrastructure gaps, training demands, and unmet psychiatric need amid accelerated policy momentum for psychedelic therapies.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

PTSD

Psychiatry Infrastructure Lags Psychedelic Momentum, With Gus Alva, MD

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

From Eosinophils to Image Biomarkers: The Evolving Science of Biologic Selection in Asthma and COPD

Vinod E. Nambudiri, MD, MBA, MPH, is affiliated with Brigham and Women's Hospital and specializes in Dermatology and Internal Medicine.

At the 2026 AAD Annual Meeting, Nambudiri spoke on various points, including how emerging AI tools may help reduce administrative burden in dermatology.

What Changes Is AI Making in Dermatology? With Vinod Nambudiri, MD, MBA, MPH

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

New psoriasis data show durable, rapid skin clearance with modern biologics, spotlighting bimekizumab’s four-year remission and patient-tailored selection.

Video Series

Treatment Selection in Psoriasis

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Teplizumab is now approved to treat stage 2 type 1 diabetes in kids 1 year and older.

Latest News

Intermittent Fasting, Calorie Restriction Deliver Similar Cardiometabolic Outcomes in T2D

Triple-Combination Blood Pressure Pill Reduces Ischemic Stroke Risk, With Craig Anderson, PhD

Lonapegsomatropin Proves Long-Term Benefit for Adult GHD in Phase 3 foresiGHt Extension Trial

FDA Expands Dupilumab to Children Aged 2 to 11 Years With Uncontrolled CSU

ICS Not Linked to Birth Defect Risk in Early Pregnancy, With Anick Bérard, PhD